Arrowhead Pharmaceuticals Inc (LTS:0HI3)
$ 20.17 0.04 (0.2%) Market Cap: 2.56 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 7.54 GF Score: 51/100

Arrowhead Pharmaceuticals Inc at UBS Global Healthcare Virtual Conference Transcript

May 26, 2021 / 07:00PM GMT
Release Date Price: $74.75
Esther P. Rajavelu
UBS Investment Bank, Research Division - Analyst & Executive Director

And thank you for joining us at the UBS Virtual Healthcare Conference. We are lucky to have Chris Anzalone from Arrowhead Pharmaceuticals for this fireside chat. And without much ado, I'll go ahead and hand over to him to maybe set us up for this call, and then we'll jump into Q&A. (Operator Instructions)

So with that, Chris, why don't you just sort of walk us through what we should be expecting for the rest of the year and some of the key catalysts?

Christopher R. Anzalone
Arrowhead Pharmaceuticals, Inc. - CEO, President & Director

Sure. So thanks very much for having us, Esther. It's really a pleasure to be here. So the good news, bad news, with us is that we have a ton going on. We'll have -- we're going to have 10 clinical programs in no time. I think we'll double that to 20 in the next few years. And so we always have a lot to think about, a lot to talk about and a lot to look forward to. Over the next couple of months, we have a number of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot